Are we closer to having drugs to treat muscle wasting disease? - Wikidata - wikimedia - TriplyDB

Are we closer to having drugs to treat muscle wasting disease?

Are we closer to having drugs to treat muscle wasting disease?

http://www.wikidata.org/entity/Q33741103

about

Cardiac cachexia: hic et nunc Dysfunction of respiratory muscles in critically ill patients on the intensive care unit Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment Sarcopenia and sarcopenic obesity: do they predict inferior oncologic outcomes after gastrointestinal cancer surgery?Moving on up: the Journal of Cachexia, Sarcopenia and Muscle.Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014.Sarcopenia: burden and challenges for public health.Virtual High-Throughput Screening To Identify Novel Activin Antagonists.Rapid screening for sarcopenia Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib Deranged iron status in psoriasis: the impact of low body mass.Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?Optimizing Ligand Efficiency of Selective Androgen Receptor Modulators (SARMs).Nutrition in cachexia: from bench to bedside.Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease.Role of interleukin-6 in cachexia: therapeutic implications.Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin.A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy.Long-term exercise training prevents mammary tumorigenesis-induced muscle wasting in rats through the regulation of TWEAK signalling.Clinical perspective for wasting in diaphragm, an ever-trained muscle Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia.Welcome to the ICD-10 code for sarcopenia.ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.Moving upwards - the journal of cachexia, sarcopenia and muscle in 2016.Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017.

P2860

Q26744140-9D746427-07A6-4563-89F6-C3A13F85932E Q26749263-3B4637E3-D0A4-4631-8883-8496E6D9DDC5 Q26775254-57BDA46A-7532-4662-8068-73BDE44BD9A1 Q28079809-A7D6E87C-077D-483C-87E0-3ACED5CB668C Q34495485-8AD616A7-B311-4031-99BB-40D7F386F8F6 Q34591010-90726E92-3106-4A7C-86D6-27707F27B407 Q35215893-CCB027BB-0C28-484A-A17C-9C0D46418F0A Q36256670-FEBED4E4-6C08-4210-99CA-04EA369F3D44 Q36349343-63EB5045-85B7-441D-8DAD-51E607609ABD Q36349363-737BDCCA-476A-4CC6-8586-0330B0A2855D Q36349371-16FC5BCA-6BED-4921-894C-76C937399C31 Q36349380-6FC880A5-42F7-43E5-8ADF-42E981898FBA Q36473163-205FC5D1-A435-4C1D-B366-A0A6BA914529 Q36679436-149AF9C2-A268-4F9E-B5CA-8348B4F63F72 Q37734762-E8B4EE47-EECF-4A61-AE2F-81002473905A Q38260561-F8047E3C-789C-484D-970C-3EDB46AD2C27 Q38931233-FDF97250-9420-4992-9547-D9D6169EDC3A Q39218137-2FE50D79-10CB-4A3C-B526-5F3D14BEF613 Q39733891-099ECD63-BA78-4C97-A378-9D9972259E56 Q41018278-2EB2AE4D-5E8C-4BCE-B36A-A2F776EEA3F8 Q41675935-013E3E4D-59E0-4BC5-80B6-E83C458C9376 Q42348565-83E9E600-345B-4C11-BDF8-43753FCCF27B Q42366308-26BA2B19-81FD-4D44-9990-C58F5F2501F4 Q42398016-79A2F4B7-1CCD-488E-AB9D-C7E0A5FCA01A Q42398018-E95D88BD-C1AE-4B8A-B50B-13CE8A4951BB Q46213438-589A4420-213F-48C4-9698-188B8015AF34

P2860

Are we closer to having drugs to treat muscle wasting disease?

http://www.wikidata.org/entity/Q33741103

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Are we closer to having drugs to treat muscle wasting disease?

@ast

Are we closer to having drugs to treat muscle wasting disease?

@en

type

label

Are we closer to having drugs to treat muscle wasting disease?

@ast

Are we closer to having drugs to treat muscle wasting disease?

@en

prefLabel

Are we closer to having drugs to treat muscle wasting disease?

@ast

Are we closer to having drugs to treat muscle wasting disease?

@en

P1433

Q33741103-4ACAD55F-4112-4801-BDA9-C04A1B2543E4

P1476

Q33741103-D3F19A76-CFDE-41FA-983A-2B889381DDFA

P2093

Q33741103-986D1B27-C633-4398-956C-844D982A24AA

P2860

Q33741103-01CB635D-D59B-4574-BB88-FE0BE7EF89A9

Q33741103-04EA7204-F4F2-43BA-8435-73DC5953A4BE

Q33741103-0C7CD246-E8CA-4CA5-9943-28EA55C5B100

Q33741103-113E92EC-D7C7-4207-9CA1-DBBF49984B46

Q33741103-128110B9-4576-415E-8555-4803EF3CE3F3

Q33741103-12B63838-2253-47EF-94E5-7DAA9DA07DF3

Q33741103-16314A51-EBE9-497F-8526-575E9C50882D

Q33741103-1AFBAECE-5654-4DC1-A708-49501AFBD53D

Q33741103-1B1F7FB4-FA65-432E-A4DC-EFDAE8E52193

Q33741103-1F30E469-BB00-40A8-9EC9-101A8669E9E4

P2888

Q33741103-66B08487-15B1-4FE3-A7B8-F70933E111DB

P304

Q33741103-2C871C55-346B-4338-986A-A899EEE8ED05

P31

Q33741103-C45327D8-6625-47B6-B681-E49261EE7ADF

Q33741103-d109f992-c389-4f44-8748-5bdaa1401c69

P356

Q33741103-EBEFE19E-D396-43F3-B803-889B3BDE3D74

P433

Q33741103-6FC579A7-6B02-46F3-AFDB-814EDA83FFCE

P478

Q33741103-4EA74938-DA61-4FCC-82B6-05F39FBB783A

P50

Q33741103-03227241-93A6-4FB5-946A-C571BEC293D1

Q33741103-AE251C8B-FD64-47D2-9541-04A07954CC47

P577

Q33741103-7A55C9FB-3C80-49D1-959C-D8E45137D23A

P5875

Q33741103-314C01A9-1B8E-4FF4-804C-B9BE26749D4D

P6179

Q33741103-148983CE-F496-44DB-AE66-C0E48EC11AB6

P698

Q33741103-9C68CD55-B5E0-49CE-967C-3F41C57A521C

P932

Q33741103-AE3E41E3-084E-4973-BB5F-0E0F54A951EA

P356

S13539-014-0149-7

P1433

Journal of Cachexia, Sarcopenia and Muscle

P1476

Are we closer to having drugs to treat muscle wasting disease?

@en

P2093

John E Morley

http://www.w3.org/2001/XMLSchema#string

P2860

Megestrol acetate for treatment of anorexia-cachexia syndrome

Protein and energy supplementation in elderly people at risk from malnutrition

Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People

An overview of sarcopenia: facts and numbers on prevalence and clinical impact

Update in inclusion body myositis

Defining a role for non-satellite stem cells in the regulation of muscle repair following exercise

Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized s

Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging

Myopenia-a new universal term for muscle wasting

Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults.

P2888

s13539-014-0149-7

P304

83-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13539-014-0149-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Stefan D. Anker

Stephan von Haehling

P577

2014-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262681971

http://www.w3.org/2001/XMLSchema#string

P6179

1042892589

http://www.w3.org/2001/XMLSchema#string

P698

24865381

http://www.w3.org/2001/XMLSchema#string

P932

4053564

http://www.w3.org/2001/XMLSchema#string